Seth Klarman’s Baupost Group eliminated its entire stake in Vaxcyte (NASDAQ:PCVX | PCVX Price Prediction) during the June quarter, according to the 13F filed August 13, 2026. The position went from 800,000 shares to zero, a reduction of 800,000 shares and a change in position value of -$46,488,000. In the same filing, Baupost also exited Willis Towers Watson (NASDAQ:WTW), reducing its position from 893,126 shares to zero, a -100% change with a position value change of -$259,632,000. Both were positions Baupost had only recently established.
The prior 13F, covering holdings as of March 31, 2026, was filed in mid-May, revealing a fresh Vaxcyte stake. Retail investors who took that as a Klarman endorsement and bought alongside him were stepping into a position that Baupost would eliminate entirely by June 30. The May stock price at the Q1 earnings filing was $56.00. By the time anyone knew Klarman had walked away, the quarter he walked away in was already six weeks over.
What the Thesis Likely Was, and Why It Broke
Vaxcyte is a clinical-stage vaccine developer with no product revenue. Its value hinges on VAX-31, a 31-valent pneumococcal conjugate vaccine being run head-to-head against competing pneumococcal vaccines in the OPUS-1 Phase 3 trial, with topline data expected in the fourth quarter of 2026. That is a binary event on a defined timeline, and value investors sometimes take pre-catalyst positions when they think the market misprices probability. It is a legitimate trade, but it is also the kind Baupost historically closes fast if the risk/reward tightens.
The financial profile makes the exit easier to rationalize. Vaxcyte reported a Q2 2026 net loss of $284.30 million on $267.85 million in R&D spending, and it leaned on a $601.80 million equity offering in February 2026 to keep the runway wide. The cash pile of $2.51 billion is real, but so is the dilution reflex any time the stock rallies into a catalyst.
WTW, by contrast, is profitable, buying back stock aggressively, and posted adjusted diluted EPS of $3.35 on $2.47 billion in revenue in Q2 2026, with a Propel AI plan targeting roughly 30% adjusted operating margin by 2028. Klarman exited anyway. That suggests the trade was opportunistic rather than a long-term conviction hold.
What This Means for a Retail Investor
A 13F is a photograph of a date already about forty-five days in the past. The May disclosure reflected only what Baupost owned on March 31, giving no visibility into subsequent positioning through May or the June exit. Following a fund into a pre-catalyst biotech based on a two-month-old snapshot is copying the setup while missing the exit.
Use 13Fs to generate ideas and to understand how sophisticated allocators size risk, then underwrite the position yourself against the actual catalyst calendar. For Vaxcyte, that calendar runs through OPUS-1 in Q4 2026 and OPUS-2 and OPUS-3 in H1 2027. Owning the thesis means being willing to sit through those readouts. Klarman was not, and his disclosure will not tell you when he changes his mind again.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks